Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

omegapharm - piperacillin sodium, quantity: 2085 mg (equivalent: piperacillin, qty 2000 mg); tazobactam sodium, quantity: 268 mg (equivalent: tazobactam, qty 250 mg) - injection, powder for - excipient ingredients: - omegapharm piperacillin and tazobactam is indicated for the treatment of serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the following conditions, - lower respiratory tract infections, - urinary tract infections (complicated and uncomplicated), - intra-abdominal infections, - skin and skin structure infections, - bacterial septicaemia, and, - gynaecological infections. children under the age of 12 years. in hospitalised children aged 2 to 12 years, omegapharm piperacillin and tazobactam is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years. . while omegapharm piperacillin and tazobactam is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing, piperacillin resistant organisms. appropriate culture and susceptibility tests sho

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

omegapharm - ceftazidime pentahydrate, quantity: 2349 mg (equivalent: ceftazidime, qty 2000 mg) - injection, powder for - excipient ingredients: sodium carbonate - omegapharm ceftazidime for injection is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. . indications include the following.. severe infections in general. for example: septicaemia (including neonatal sepsis), bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns.. respiratory tract. for example: pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis.. severe ear, nose and throat infections. for example: otitis media, mastoiditis.. urinary tract. for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only); infections associated with bladder and renal stones.. skin and soft tissue. . for e

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

omegapharm - ceftazidime pentahydrate, quantity: 1175 mg (equivalent: ceftazidime, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - omegapharm ceftazidime for injection is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. . indications include the following.. severe infections in general. for example: septicaemia (including neonatal sepsis), bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns.. respiratory tract. for example: pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis.. severe ear, nose and throat infections. for example: otitis media, mastoiditis.. urinary tract. for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only); infections associated with bladder and renal stones.. skin and soft tissue. . for e

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - omega-3-acid ethyl esters 90 - capsules, soft - 1000 milligram

ABD - İngilizce - NLM (National Library of Medicine)

international brand management, llc - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 1 g in 1 g - each capsule contains 1 gram of omega-3-acid ethyl esters liquid concentrate consisting of at least 900 mg of omega-3-acid ethyl esters.

ABD - İngilizce - NLM (National Library of Medicine)

atlantic biologicals corps - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 900 mg - lovaza® (omega-3-acid ethyl esters) is indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (greater than or equal to 500 mg per dl) hypertriglyceridemia (htg). usage considerations: patients should be placed on an appropriate lipid-lowering diet before receiving lovaza and should continue this diet during treatment with lovaza. laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with lovaza. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. limitations of use: the effect of lovaza on the risk for

ABD - İngilizce - NLM (National Library of Medicine)

trigen laboratories, inc. - omega-3 fatty acids (unii: 71m78end5s) (omega-3 fatty acids - unii:71m78end5s), linoleic acid (unii: 9kjl21t0qj) (linoleic acid - unii:9kjl21t0qj), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol acetate, dl- (unii: wr1wpi7ew8) (.alpha.-tocopherol, dl- - unii:7qwa1rio01), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2 - omega-3 fatty acids 330 mg - ultimatecare one is indicated to provide vitamin/mineral and omega-3 fatty acid supplementation throughout pregnancy, during the postnatal period for both lactating and non-lactating mothers, and throughout the childbearing years. it is also useful for improving nutritional status prior to conception. this product is contraindicated in patients with known hypersensitivity to any of the ingredients.

ABD - İngilizce - NLM (National Library of Medicine)

everett laboratories, inc. - omega-3 fatty acids (unii: 71m78end5s) (doconexent - unii:zad9okh9jc), niacin (unii: 2679mf687a) (niacinamide - unii:25x51i8rd4), .alpha.-tocopherol (unii: h4n855pnz1) (.alpha.-tocopherol - unii:h4n855pnz1), vitamin d (unii: 9vu1ki44gp) (cholecalciferol - unii:1c6v77qf41), lauric acid (unii: 1160n9nu9u) (lauric acid - unii:1160n9nu9u), vitamin a (unii: 81g40h8b0t) (.beta.-carotene - unii:01yae03m7j), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), thiamine mononitrate (unii: 8k0i0 - omega-3 fatty acids 200 mg - vitafol® -plus is indicated to provide vitamin, mineral and omega-3 fatty acid supplementation prior to conception, throughout pregnancy, and during the postnatal period for the lactating and non-lactating mother, including individuals with known allergies to fish. vitafol® -plus does not contain fish, fish oils, fish proteins or fish byproducts. vitafol® -plus is contraindicated in patients with hypersensitivity to any of its components or color additives. folic acid is contraindicated in patients with untreated and uncomplicated pernicious anemia, and in those with anaphylactic sensitivity to folic acid. iron therapy is contraindicated in patients with hemochromatosis and patients with iron storage disease or the potential for iron storage disease due to chronic hemolytic anemia (e.g., inherited anomalies of hemoglobin structure or synthesis and/or red cell enzyme deficiencies, etc), pyridoxine responsive anemia, or cirrhosis of the liver. cyanocobalamin is contraindicated in patients with sensitivity to co

ABD - İngilizce - NLM (National Library of Medicine)

atlantic biologicals corps - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 900 mg - lovaza (omega-3-acid ethyl esters) is indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (≥500 mg/dl) hypertriglyceridemia (htg). ® patients should be placed on an appropriate lipid-lowering diet before receiving lovaza and should continue this diet during treatment with lovaza. usage considerations: laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with lovaza. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. limitations of use: the effect

Japonya - İngilizce - すりの適正使用協議会 RAD-AR Council, Japan

teva takeda pharma ltd. - omega-3-acid ethyl esters - colorless to light-yellow clear spherical capsule, diameter: approx. 4 mm